135 related articles for article (PubMed ID: 11394656)
1. Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice.
Merle P; Chevallier M; Levy R; Maisonnas M; Terradillos O; Ahmed SNS ; Trépo C; Buendia MA; Vitvitski-Trépo L
J Hepatol; 2001 Apr; 34(4):562-9. PubMed ID: 11394656
[TBL] [Abstract][Full Text] [Related]
2. Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice.
Merle P; Barraud L; Lefrançois L; Chevallier M; Guerret S; Maisonnas M; Bordes I; Savre-Train I; Trepo C; Vitvitski-Trepo L
Oncogene; 2003 May; 22(18):2762-71. PubMed ID: 12743599
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of interferon alpha in primary prevention of preneoplastic lesions in a transgenic murine model of hepatocellular carcinoma related to the interaction between woodchuck hepatitis viruses and c-myc oncogene].
Merle P; Levy R; Vitvitski L; Chevallier M; Buendia MA; Trepo C
Gastroenterol Clin Biol; 1997; 21(6-7):459-65. PubMed ID: 9295972
[TBL] [Abstract][Full Text] [Related]
4. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Amicone L; Terradillos O; Calvo L; Costabile B; Cicchini C; Della Rocca C; Lozupone F; Piacentini M; Buendia MA; Tripodi M
Oncogene; 2002 Feb; 21(9):1335-45. PubMed ID: 11857077
[TBL] [Abstract][Full Text] [Related]
5. Hepatocarcinogenesis in woodchuck hepatitis virus/c-myc mice: sustained cell proliferation and biphasic activation of insulin-like growth factor II.
Liu P; Terradillos O; Renard CA; Feldmann G; Buendia MA; Bernuau D
Hepatology; 1997 Apr; 25(4):874-83. PubMed ID: 9096591
[TBL] [Abstract][Full Text] [Related]
6. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
7. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.
Terradillos O; Billet O; Renard CA; Levy R; Molina T; Briand P; Buendia MA
Oncogene; 1997 Jan; 14(4):395-404. PubMed ID: 9053836
[TBL] [Abstract][Full Text] [Related]
8. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat.
Nakaji M; Yano Y; Ninomiya T; Seo Y; Hamano K; Yoon S; Kasuga M; Teramoto T; Hayashi Y; Yokozaki H
Carcinogenesis; 2004 Mar; 25(3):389-97. PubMed ID: 14633663
[TBL] [Abstract][Full Text] [Related]
9. Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.
Llorente Izquierdo C; Mayoral R; Flores JM; García-Palencia P; Cucarella C; Boscá L; Casado M; Martín-Sanz P
Am J Pathol; 2011 Mar; 178(3):1361-73. PubMed ID: 21356386
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis.
Oh BK; Kim YJ; Park YN; Choi J; Kim KS; Park C
Am J Gastroenterol; 2006 Apr; 101(4):831-8. PubMed ID: 16494581
[TBL] [Abstract][Full Text] [Related]
11. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis.
Pang R; Lee TK; Poon RT; Fan ST; Wong KB; Kwong YL; Tse E
Gastroenterology; 2007 Mar; 132(3):1088-103. PubMed ID: 17383430
[TBL] [Abstract][Full Text] [Related]
12. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion.
Etiemble J; Degott C; Renard CA; Fourel G; Shamoon B; Vitvitski-Trépo L; Hsu TY; Tiollais P; Babinet C; Buendia MA
Oncogene; 1994 Mar; 9(3):727-37. PubMed ID: 8108115
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells.
You X; Liu F; Zhang T; Lv N; Liu Q; Shan C; Du Y; Kong G; Wang T; Ye L; Zhang X
Oncogene; 2014 Jan; 33(4):449-60. PubMed ID: 23318446
[TBL] [Abstract][Full Text] [Related]
14. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of pegylated interferon in the rat hepatocarcinogenesis model.
Miki A; Yano Y; Kato H; Seo Y; Kuriyama M; Azuma T; Hayashi Y
Int J Oncol; 2008 Mar; 32(3):603-8. PubMed ID: 18292937
[TBL] [Abstract][Full Text] [Related]
16. Infection of WHV/c-myc transgenic mice with Moloney murine leukaemia virus and proviral insertion near the syndecan-4 gene in an early liver tumour.
Renard CA; Transy C; Tiollais P; Buendia MA
Res Virol; 1998; 149(3):133-43. PubMed ID: 9711537
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection.
Tennant BC; Toshkov IA; Peek SF; Jacob JR; Menne S; Hornbuckle WE; Schinazi RD; Korba BE; Cote PJ; Gerin JL
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S283-93. PubMed ID: 15508096
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
Scand J Gastroenterol; 2005 Jun; 40(6):688-96. PubMed ID: 16036529
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma.
Deng M; Hou J; Hu J; Wang S; Chen M; Chen L; Ju Y; Li C; Meng S
Cancer Lett; 2016 Dec; 383(1):62-72. PubMed ID: 27693636
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of human cervical cancer proto-oncogene contributes to hepatitis B virus-induced malignant transformation of hepatocyte by down-regulating E-cadherin.
Li J; Dai X; Zhang H; Zhang W; Sun S; Gao T; Kou Z; Yu H; Guo Y; Du L; Jiang S; Zhang J; Zhou Y
Oncotarget; 2015 Oct; 6(30):29196-208. PubMed ID: 26470691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
